Investor mix
10 investors on record; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 6 | 60% |
| Private equity | 2 | 20% |
| Bank & private debt | 1 | 10% |
| Other / undisclosed | 1 | 10% |
Developing antibodies and antibody-drug conjugates (ADCs) to target cancer stem cells.
10 investors on record; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 6 | 60% |
| Private equity | 2 | 20% |
| Bank & private debt | 1 | 10% |
| Other / undisclosed | 1 | 10% |